Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

AI-driven Discovery of Celecoxib and Dexamethasone for Exploring their Mode of Action as Human Interleukin (IL-6) Inhibitors to Treat COVID-19-induced Cytokine Storm in Humans

Author(s): Israa M. Shamkh*, Mahmoud Elkazzaz, Enas. S. Radwan, Jawayria Najeeb, Md. Tabish Rehman, Mohamed F. AlAjmi, Moayad Shahwan, Muhammad Sufyan, Nouf Khalifa Alaqeel, Ibrahim A. Ibrahim, Basit Jabbar, Mohammad Shahbaz Khan, Tomasz M. Karpiński, Abdullah Haikal*, Reem M. Aljowaie, Saeedah Musaed Almutairi and Amr Ahmed

Volume 29, Issue 34, 2023

Published on: 25 October, 2023

Page: [2752 - 2762] Pages: 11

DOI: 10.2174/0113816128260449231017091824

Price: $65

Abstract

Background: In the case of COVID-19 patients, it has been observed that the immune system of the infected person exhibits an extreme inflammatory response known as cytokine release syndrome (CRS) where the inflammatory cytokines are swiftly produced in quite large amounts in response to infective stimuli. Numerous case studies of COVID-19 patients with severe symptoms have documented the presence of higher plasma concentrations of human interleukin-6 (IL-6), which suggests that IL-6 is a crucial factor in the pathophysiology of the disease. In order to prevent CRS in COVID-19 patients, the drugs that can exhibit binding interactions with IL-6 and block the signaling pathways to decrease the IL-6 activity may be repurposed.

Methods: This research work focused on molecular docking-based screening of the drugs celecoxib (CXB) and dexamethasone (DME) to explore their potential to interact with the binding sites of IL-6 protein and reduce the hyper-activation of IL-6 in the infected personnel.

Results: Both of the drugs were observed to bind with the IL-6 (IL-6 receptor alpha chain) and IL-6Rα receptor with the respective affinities of -7.3 kcal/mol and -6.3 kcal/mol, respectively, for CXB and DME. Moreover, various types of binding interactions of the drugs with the target proteins were also observed in the docking studies. The dynamic behaviors of IL-6/IL-6Rα in complex with the drugs were also explored through molecular dynamics simulation analysis. The results indicated significant stabilities of the acquired drug-protein complexes up to 100 ns.

Conclusion: The findings of this study have suggested the potential of the drugs studied to be utilized as antagonists for countering CRS in COVID-19 ailment. This study presents the studied drugs as promising candidates both for the clinical and pre-clinical treatment of COVID-19.

Keywords: COVID-19, interleukin-6, celecoxib, dexamethasone, molecular docking, molecular dynamics simulation.

« Previous
[1]
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3): 181-92.
[http://dx.doi.org/10.1038/s41579-018-0118-9] [PMID: 30531947]
[2]
Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun 2020; 87: 59-73.
[http://dx.doi.org/10.1016/j.bbi.2020.04.046] [PMID: 32334062]
[3]
Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 2003; 362(9393): 1353-8.
[http://dx.doi.org/10.1016/S0140-6736(03)14630-2] [PMID: 14585636]
[4]
Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020; 92(4): 401-2.
[http://dx.doi.org/10.1002/jmv.25678] [PMID: 31950516]
[5]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[6]
Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 2020; 111: 102452.
[http://dx.doi.org/10.1016/j.jaut.2020.102452] [PMID: 32291137]
[7]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-42.
[8]
Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev 2020; 53: 13-24.
[http://dx.doi.org/10.1016/j.cytogfr.2020.05.009] [PMID: 32475759]
[9]
Negahdaripour M, Mosaddeghi P, Shahabinezhad F, et al. Therapeutic approaches for COVID-19 based on the interferon-mediated immune responses. Curr Signal Transduct Ther 2021; 16(3): 269-79.
[http://dx.doi.org/10.2174/1574362416666210120104636]
[10]
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[11]
Atal S, Fatima Z, Balakrishnan S. Approval of itolizumab for COVID-19: A premature decision or need of the hour? BioDrugs 2020; 34(6): 705-11.
[http://dx.doi.org/10.1007/s40259-020-00448-5] [PMID: 33048300]
[12]
Hamdi A, Elhusseiny WM, Othman DIA, et al. Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethia-zolidine-2,4-dione derivatives: Histone deacetylases inhibitory activity and molecular docking study. Eur J Med Chem 2022; 244: 114827.
[http://dx.doi.org/10.1016/j.ejmech.2022.114827] [PMID: 36242988]
[13]
Hamdi A, Yaseen M, Ewes WA, et al. Development of new thiazolidine-2,4-dione hybrids as aldose reductase inhibitors endowed with antihyperglycaemic activity: Design, synthesis, biological investigations, and in silico insights. J Enzyme Inhib Med Chem 2023; 38(1): 2231170.
[http://dx.doi.org/10.1080/14756366.2023.2231170] [PMID: 37470409]
[14]
Ishiguro H, Kawahara T, Li Y, Miyamoto H. Anti-tumor activities of dexamethasone. Dexamethasone: Therapeutic uses, mechanism of action and potential side effects 2013; 117-36.
[15]
London NJS, Chiang A, Haller JA. The dexamethasone drug delivery system: Indications and evidence. Adv Ther 2011; 28(5): 351-66.
[http://dx.doi.org/10.1007/s12325-011-0019-z] [PMID: 21494891]
[16]
Allen K. Dexamethasone: An all purpose agent? Australasian Anaesthesia 2007; 2007: 65-70.
[17]
Lammers T, Sofias AM, van der Meel R, et al. Dexamethasone nanomedicines for COVID-19. Nat Nanotechnol 2020; 15(8): 622-4.
[http://dx.doi.org/10.1038/s41565-020-0752-z] [PMID: 32747742]
[18]
Lai CC, Ko WC, Lee PI, Jean SS, Hsueh PR. Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents 2020; 56(2): 106024.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106024] [PMID: 32450197]
[19]
Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother 2020; 64(6): e00483-20.
[http://dx.doi.org/10.1128/AAC.00483-20] [PMID: 32205349]
[20]
Fidahic M, Kadic AJ, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2017; 6(6): CD012095.
[http://dx.doi.org/10.1002/14651858.CD012095.pub2]
[21]
Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P. Celecoxib for osteoarthritis. Cochrane Database Syst Rev 2017; 5(5): CD009865.
[http://dx.doi.org/10.1002/14651858.CD009865.pub2]
[22]
Khupse R, Dixit P. Potential antiviral mechanism of hydroxychloroquine in COVID-19 and further extrapolation to celecoxib (Celebrex) for future clinical trials. SSRN 3570102.2020;
[http://dx.doi.org/10.2139/ssrn.3570102]
[23]
Hong W, Chen Y, You K, et al. Celebrex adjuvant therapy on COVID-19: An experimental study. MedRxiv 2020.
[http://dx.doi.org/10.1101/2020.05.05.20077610]
[24]
Gimeno A, Mestres-Truyol J, Ojeda-Montes MJ, et al. Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition. Int J Mol Sci 2020; 21(11): 3793.
[http://dx.doi.org/10.3390/ijms21113793] [PMID: 32471205]
[25]
Luedemann M, Stadler D, Cheng CC, Protzer U, Knolle PA, Donakonda S. Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing. Comput Struct Biotechnol J 2022; 20: 799-811.
[http://dx.doi.org/10.1016/j.csbj.2022.01.024] [PMID: 35126884]
[26]
Abdalla M, Mohapatra RK, Sarangi AK, et al. In silico studies on phytochemicals to combat the emerging COVID-19 infection. J Saudi Chem Soc 2021; 25(12): 101367.
[http://dx.doi.org/10.1016/j.jscs.2021.101367]
[27]
Ononamadu CJ, Abdalla M, Ihegboro GO, et al. In silico identification and study of potential anti-mosquito juvenile hormone binding protein (MJHBP) compounds as candidates for dengue virus - Vector insecticides. Biochem Biophys Rep 2021; 28: 101178.
[http://dx.doi.org/10.1016/j.bbrep.2021.101178] [PMID: 34901473]
[28]
Murtaza S, Kausar N, Arshad U, et al. Novel 2-aminobenzo-hydrazide derivatives, design, synthesis, anti-Alzheimer evaluation, SAR studies and molecular docking analysis. J Mol Struct 2022; 1264: 133271.
[http://dx.doi.org/10.1016/j.molstruc.2022.133271]
[29]
Niu W, Wu F, Cao W, et al. Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6. Biosci Rep 2021; 41(1): BSR20202583.
[http://dx.doi.org/10.1042/BSR20202583] [PMID: 33146673]
[30]
Srivastava K, Singh MK. Drug repurposing in COVID-19: A review with past, present and future. Metabolism Open 2021; 12: 100121.
[http://dx.doi.org/10.1016/j.metop.2021.100121] [PMID: 34462734]
[31]
Malik A, Naz A, Ahmad S, et al. Inhibitory potential of phytochemicals on interleukin-6-mediated T-cell reduction in COVID-19 patients: A computational approach. Bioinform Biol Insights 2021; 15.
[http://dx.doi.org/10.1177/11779322211021430] [PMID: 34163151]
[32]
Verma A, Kumar P, Pauly I, et al. Current insights and molecular docking studies of the drugs under clinical trial as RdRp inhibitors in COVID-19 treatment. Curr Pharm Des 2022; 28(46): 3677-705.
[http://dx.doi.org/10.2174/1381612829666221107123841] [PMID: 36345244]
[33]
Arooj M, Shehadi I, Nassab CN, Mohamed AA. Computational insights into binding mechanism of drugs as potential inhibitors against SARS-CoV-2 targets. Chem Zvesti 2022; 76(1): 111-21.
[http://dx.doi.org/10.1007/s11696-021-01843-0] [PMID: 34483461]
[34]
Tran QH, Nguyen QT, Tran TTN, et al. Identification of small molecules as potential inhibitors of interleukin 6: A multi-computational investigation. Mol Divers 2022; 1-16.
[http://dx.doi.org/10.1007/s11030-022-10558-7] [PMID: 36319930]
[35]
Jawarkar RD, Sharma P, Jain N, et al. QSAR, molecular docking, MD simulation and MMGBSA calculations approaches to recognize concealed pharmacophoric features requisite for the optimization of ALK tyrosine kinase inhibitors as anticancer leads. Molecules 2022; 27(15): 4951.
[http://dx.doi.org/10.3390/molecules27154951] [PMID: 35956900]
[36]
Castro-Alvarez A, Costa A, Vilarrasa J. The performance of several docking programs at reproducing protein–macrolide-like crystal structures. Molecules 2017; 22(1): 136.
[http://dx.doi.org/10.3390/molecules22010136] [PMID: 28106755]
[37]
Enayatkhani M, Salimi M, Azadmanesh K, Teimoori-Toolabi L. In-silico identification of new inhibitors for low-density lipoprotein receptor-related protein6 (LRP6). J Biomol Struct Dyn 2022; 40(10): 4440-50.
[http://dx.doi.org/10.1080/07391102.2020.1857843] [PMID: 33351722]
[38]
Shamkh IM, Pratiwi D. Development of SARS-CoV-2 inhibitors using molecular docking study with different coronavirus spike protein and ACE2. J Mol Dock 2021; 1(1): 1-14.
[http://dx.doi.org/10.33084/jmd.v1i1.2212]
[39]
Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31(2): 455-61.
[PMID: 19499576]
[40]
Rashid H, Ahmad N, Abdalla M, Khan K, Martines MAU, Shabana S. Molecular docking and dynamic simulations of Cefixime, Etoposide and Nebrodenside A against the pathogenic proteins of SARS-CoV-2. J Mol Struct 2022; 1247: 131296.
[http://dx.doi.org/10.1016/j.molstruc.2021.131296] [PMID: 34404957]
[41]
Kalamatianos K. Drug repurposing for coronavirus (COVID-19): In silico screening of known drugs against the SARS-CoV-2 spike protein bound to angiotensin converting enzyme 2 (ACE2)(6M0J). 2021.
[42]
Gupta M, Ha K, Agarwal R, Quarles LD, Smith JC. Molecular dynamics analysis of the binding of human interleukin‐6 with interleukin‐6 α‐receptor. Proteins 2021; 89(2): 163-73.
[http://dx.doi.org/10.1002/prot.26002] [PMID: 32881084]
[43]
Zothantluanga JH, Abdalla M, Rudrapal M, Tian Q, Chetia D, Li J. Computational investigations for identification of bioactive molecules from Baccaurea ramiflora and Bergenia ciliata as inhibitors of SARS-CoV-2 Mpro. Polycycl Aromat Compd 2022; 1-29.
[44]
Abdalla M, Eltayb WA, El-Arabey AA, Singh K, Jiang X. Molecular dynamic study of SARS-CoV-2 with various S protein mutations and their effect on thermodynamic properties. Comput Biol Med 2022; 141: 105025.
[http://dx.doi.org/10.1016/j.compbiomed.2021.105025] [PMID: 34772510]
[45]
Shamkh IM, Pratiwi D, Omar HS, Reyad NE. In silico study for similar FDA approved drugs as inhibitors of SARS-CoV-2 Spike and the host receptor proteins. J Mol Docking 2021; 1(2): 49-58.
[http://dx.doi.org/10.33084/jmd.v1i2.2213]
[46]
Elkazzaz M, Ahmed A, Abo-Amer YEE, et al. In silico discovery of gpcrs and gnrhrs as novel binding receptors of SARS-CoV-2 Spike protein could explain neuroendocrine disorders in COVID-19. Vaccines (Basel) 2022; 10(9): 1500.
[http://dx.doi.org/10.3390/vaccines10091500] [PMID: 36146578]

Rights & Permissions Print Cite
Article Metrics
17
2
© 2024 Bentham Science Publishers | Privacy Policy